BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 17018786)

  • 1. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
    Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
    J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
    Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA
    Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.
    Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck A; Danforth KN; Park Y; Brinton LA
    Br J Cancer; 2012 Sep; 107(7):1181-7. PubMed ID: 22929888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone therapy and ovarian cancer.
    Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
    JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of postmenopausal hormone use and ovarian cancer risk.
    Danforth KN; Tworoger SS; Hecht JL; Rosner BA; Colditz GA; Hankinson SE
    Br J Cancer; 2007 Jan; 96(1):151-6. PubMed ID: 17179984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone therapy and ovarian borderline tumors: a national cohort study.
    Mørch LS; Løkkegaard E; Andreasen AH; Kjær SK; Lidegaard Ø
    Cancer Causes Control; 2012 Jan; 23(1):113-20. PubMed ID: 22037908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy and different ovarian cancers: a national cohort study.
    Mørch LS; Løkkegaard E; Andreasen AH; Kjaer SK; Lidegaard O
    Am J Epidemiol; 2012 Jun; 175(12):1234-42. PubMed ID: 22517811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
    Chang SC; Lacey JV; Brinton LA; Hartge P; Adams K; Mouw T; Carroll L; Hollenbeck A; Schatzkin A; Leitzmann MF
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):723-30. PubMed ID: 17416763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menopausal hormones and risk of ovarian cancer.
    Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
    Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort.
    Brinton LA; Schwartz L; Spitz MR; Park Y; Hollenbeck AR; Gierach GL
    Cancer Causes Control; 2012 Mar; 23(3):487-96. PubMed ID: 22367699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
    Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
    Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menopausal hormone replacement therapy and risk of ovarian cancer.
    Lacey JV; Mink PJ; Lubin JH; Sherman ME; Troisi R; Hartge P; Schatzkin A; Schairer C
    JAMA; 2002 Jul; 288(3):334-41. PubMed ID: 12117398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?
    Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck AR; Park Y; Brinton LA
    Int J Cancer; 2013 Jan; 132(2):417-26. PubMed ID: 22553145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
    Beral V; Reeves G; Bull D; Green J;
    J Natl Cancer Inst; 2011 Feb; 103(4):296-305. PubMed ID: 21278356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
    Grady D; Gebretsadik T; Kerlikowske K; Ernster V; Petitti D
    Obstet Gynecol; 1995 Feb; 85(2):304-13. PubMed ID: 7824251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.